Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR5A | P47898 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ACHE | P22303 | 9/20 | 0.46 |
| ▸ | BACE1 | P56817 | 9/20 | 0.46 |
| ▸ | BCHE | P06276 | 6/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.44 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.44 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.44 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.43 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.42 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11366530 | 0.87 | KMT2A (0.52) | KMT2AMCHR1AOC3 | |
| SCHEMBL11423711 | 0.86 | AOC3 (0.60) | HTR5AACHEBACE1BCHEAOC3 | |
| SCHEMBL11421859 | 0.85 | DRD2 (0.60) | MCHR1 | |
| SCHEMBL11357938 | 0.85 | CHRM4 (0.49) | ACHESUCNR1AOC3NPFFR1NPFFR2 | |
| SCHEMBL11419626 | 0.85 | HDAC3 (0.51) | ACHEBCHEAOC3 | |
| SCHEMBL11424224 | 0.83 | USP30 (0.49) | MEN1KMT2AACHEBCHEMCHR1 | |
| SCHEMBL19496656 | 0.79 | HTR5A (0.69) | HTR5AMEN1KMT2AACHEBACE1 | |
| SCHEMBL11422215 | 0.78 | AOC3 (0.49) | AOC3 | |
| SCHEMBL11356204 | 0.78 | AOC3 (0.51) | AOC3 | |
| SCHEMBL11357366 | 0.78 | AOC3 (0.57) | AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479165-B1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC (JP) | 2017-10-25 | — | — | EP | disclosed |
| US-8802679-B2 | Glycine compound | ASTELLAS PHARMA INC. (JP) | 2014-08-12 | — | — | US | disclosed |
| US-20120184520-A1 | GLYCINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-07-19 | — | — | US | disclosed |
| WO-2011034078-A1 | GLYCINE COMPOUND | アステラス製薬株式会社 (JP) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184520-A1 | GLYCINE COMPOUND | SLC5A1, AQP1, VAPB | HTR5A 4080/4885MEN1 2825/4885KMT2A 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.